International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Amgen Announced the United States Food and Drug Administration (FDA) Approval of AMJEVITA™

Psoriasis News Amgen Blog Graphic

Amgen announced the United States Food and Drug Administration (FDA) approval of AMJEVITA™ for treating adults with plaque psoriasis and psoriatic arthritis. AMJEVITA™ is a biosimilar to Humira® and the first of several other biosimilars expected to be approved later this year. AMJEVITA is citrate-free and will be available in prefilled syringe and autoinjector presentations.

Categories

Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.